Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of talen-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC Meeting Abstract
| Authors: | Betof, A.; Wise-Draper, T.; He, K.; Sarnaik, A.; Thompson, J.; Finckenstein, F.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Chesney, J. |
| Abstract Title: | Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of talen-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A815 |
| Language: | English |
| ACCESSION: | WOS:000919423400739 |
| DOI: | 10.1136/jitc-2022-SITC2022.0783 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 783 -- Source: Wos |
